A digitally supported multimodal lifestyle program to promote brain health among older adults (the LETHE randomized controlled feasibility trial): study design, progress, and first results.

IF 7.9 1区 医学 Q1 CLINICAL NEUROLOGY Alzheimer's Research & Therapy Pub Date : 2024-11-21 DOI:10.1186/s13195-024-01615-4
Anna Rosenberg, Helena Untersteiner, Anna Giulia Guazzarini, Markus Bödenler, Jeroen Bruinsma, Bianca Buchgraber-Schnalzer, Matteo Colombo, Rik Crutzen, Ana Diaz, Dimitrios I Fotiadis, Hannes Hilberger, Simone Huber, Nico Kaartinen, Thomas Kassiotis, Miia Kivipelto, Jenni Lehtisalo, Vasileios S Loukas, Jyrki Lötjönen, Mattia Pirani, Charlotta Thunborg, Sten Hanke, Francesca Mangialasche, Patrizia Mecocci, Elisabeth Stögmann, Tiia Ngandu
{"title":"A digitally supported multimodal lifestyle program to promote brain health among older adults (the LETHE randomized controlled feasibility trial): study design, progress, and first results.","authors":"Anna Rosenberg, Helena Untersteiner, Anna Giulia Guazzarini, Markus Bödenler, Jeroen Bruinsma, Bianca Buchgraber-Schnalzer, Matteo Colombo, Rik Crutzen, Ana Diaz, Dimitrios I Fotiadis, Hannes Hilberger, Simone Huber, Nico Kaartinen, Thomas Kassiotis, Miia Kivipelto, Jenni Lehtisalo, Vasileios S Loukas, Jyrki Lötjönen, Mattia Pirani, Charlotta Thunborg, Sten Hanke, Francesca Mangialasche, Patrizia Mecocci, Elisabeth Stögmann, Tiia Ngandu","doi":"10.1186/s13195-024-01615-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) multimodal lifestyle intervention yielded cognitive and other health benefits in older adults at risk of cognitive decline. The two-year multinational randomized controlled LETHE trial evaluates the feasibility of a digitally supported, adapted FINGER intervention among at-risk older adults. Technology is used to complement in-person activities, streamline the intervention delivery, personalize recommendations, and collect digital biomarkers.</p><p><strong>Methods: </strong>Trial includes older adults (60-77 years) with digital readiness/experience with smart devices and increased dementia risk but without substantial cognitive impairment. Participants are enrolled at four sites (Austria, Finland, Italy, Sweden). At baseline, participants were randomized 1:1 ratio to 1) intervention i.e., structured multimodal lifestyle program (including diet, exercise, cognitive training, vascular/metabolic risk management, social stimulation, sleep/stress management) where in-person activities led by professionals are supported with an Android mobile phone application developed by the consortium (the LETHE App); or 2) control i.e., self-guided program (regular health advice; simplified App with no personalized/interactive content). All participants wear smartwatches to gather passive data (e.g., physical activity, sleep). Primary outcomes are retention, adherence, and change in validated dementia risk scores. Secondary outcomes include changes in lifestyle, cognition, stress, sleep, health-related quality of life, and health literacy. Additional outcomes (exploratory) include e.g. participant experiences and dementia-related biomarkers (Alzheimer's disease blood markers, neuroimaging). A sub-study explores the feasibility of novel interactive technology (audio glasses, social robot).</p><p><strong>Results: </strong>Recruitment began in September 2022, and the last participant was randomized in June 2023. In total, 156 individuals were randomized (mean age 69 years, 65% women; balanced recruitment across the four sites). Vascular and lifestyle risk factors were common (e.g., 65% with hypertension, 69% with hypercholesterolemia, 39% physically inactive), indicating successful recruitment of a population with risk reduction potential. Trial will be completed by summer 2025. Retention until the first post-baseline visit at 6 months is high (n = 2 discontinued, retention 98.7%).</p><p><strong>Conclusion: </strong>LETHE provides crucial information about the feasibility of technology and a digitally supported FINGER lifestyle program to promote brain health. Digital tools specifically designed for older adults could offer potential for large-scale, cost-effective prevention programs.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (NCT05565170).</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"252"},"PeriodicalIF":7.9000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-024-01615-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) multimodal lifestyle intervention yielded cognitive and other health benefits in older adults at risk of cognitive decline. The two-year multinational randomized controlled LETHE trial evaluates the feasibility of a digitally supported, adapted FINGER intervention among at-risk older adults. Technology is used to complement in-person activities, streamline the intervention delivery, personalize recommendations, and collect digital biomarkers.

Methods: Trial includes older adults (60-77 years) with digital readiness/experience with smart devices and increased dementia risk but without substantial cognitive impairment. Participants are enrolled at four sites (Austria, Finland, Italy, Sweden). At baseline, participants were randomized 1:1 ratio to 1) intervention i.e., structured multimodal lifestyle program (including diet, exercise, cognitive training, vascular/metabolic risk management, social stimulation, sleep/stress management) where in-person activities led by professionals are supported with an Android mobile phone application developed by the consortium (the LETHE App); or 2) control i.e., self-guided program (regular health advice; simplified App with no personalized/interactive content). All participants wear smartwatches to gather passive data (e.g., physical activity, sleep). Primary outcomes are retention, adherence, and change in validated dementia risk scores. Secondary outcomes include changes in lifestyle, cognition, stress, sleep, health-related quality of life, and health literacy. Additional outcomes (exploratory) include e.g. participant experiences and dementia-related biomarkers (Alzheimer's disease blood markers, neuroimaging). A sub-study explores the feasibility of novel interactive technology (audio glasses, social robot).

Results: Recruitment began in September 2022, and the last participant was randomized in June 2023. In total, 156 individuals were randomized (mean age 69 years, 65% women; balanced recruitment across the four sites). Vascular and lifestyle risk factors were common (e.g., 65% with hypertension, 69% with hypercholesterolemia, 39% physically inactive), indicating successful recruitment of a population with risk reduction potential. Trial will be completed by summer 2025. Retention until the first post-baseline visit at 6 months is high (n = 2 discontinued, retention 98.7%).

Conclusion: LETHE provides crucial information about the feasibility of technology and a digitally supported FINGER lifestyle program to promote brain health. Digital tools specifically designed for older adults could offer potential for large-scale, cost-effective prevention programs.

Trial registration: ClinicalTrials.gov (NCT05565170).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
促进老年人大脑健康的数字支持多模式生活方式计划(LETHE 随机对照可行性试验):研究设计、进展和初步结果。
背景:芬兰预防认知障碍和残疾的老年干预研究(FINGER)多模式生活方式干预对有认知能力下降风险的老年人的认知能力和其他健康产生了益处。为期两年的多国随机对照 LETHE 试验评估了在高危老年人中采用数字支持的、经过调整的 FINGER 干预措施的可行性。技术被用来补充面对面的活动、简化干预措施的实施、个性化建议以及收集数字生物标志物:试验对象包括具有使用智能设备的数字准备/经验、痴呆风险增加但无严重认知障碍的老年人(60-77 岁)。参与者在四个地点(奥地利、芬兰、意大利和瑞典)注册。在基线阶段,参与者按 1:1 的比例被随机分配到:1)干预,即结构化多模式生活方式计划(包括饮食、运动、认知训练、血管/代谢风险管理、社交刺激、睡眠/压力管理),其中由专业人士指导的亲身活动由联盟开发的安卓手机应用程序(LETHE App)提供支持;或 2)对照,即自我指导计划(定期健康建议;简化的应用程序,无个性化/交互式内容)。所有参与者均佩戴智能手表收集被动数据(如体力活动、睡眠)。主要结果包括保留率、坚持率和验证痴呆症风险评分的变化。次要结果包括生活方式、认知、压力、睡眠、与健康相关的生活质量和健康素养的变化。其他结果(探索性)包括参与者的经历和痴呆症相关生物标志物(阿尔茨海默氏症血液标志物、神经影像学)等。一项子研究探讨了新型互动技术(音频眼镜、社交机器人)的可行性:招募工作于 2022 年 9 月开始,最后一名参与者于 2023 年 6 月被随机分配。共有 156 人被随机选中(平均年龄 69 岁,65% 为女性;四个地点的招募情况均衡)。血管和生活方式风险因素很常见(例如,65%的人患有高血压,69%的人患有高胆固醇血症,39%的人缺乏运动),这表明成功招募到了具有降低风险潜力的人群。试验将于 2025 年夏季完成。直到6个月后首次基线访问前的保留率很高(n = 2人中止,保留率为98.7%):LETHE提供了有关技术可行性的重要信息,以及促进大脑健康的数字支持FINGER生活方式计划。专为老年人设计的数字工具可为大规模、具有成本效益的预防计划提供潜力:试验注册:ClinicalTrials.gov (NCT05565170)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Alzheimer's Research & Therapy
Alzheimer's Research & Therapy 医学-神经病学
CiteScore
13.10
自引率
3.30%
发文量
172
审稿时长
>12 weeks
期刊介绍: Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.
期刊最新文献
Elevated plasma p-tau231 is associated with reduced generalization and medial temporal lobe dynamic network flexibility among healthy older African Americans. Can the clinical sign "head-turning sign" and simple questions in "Neucop-Q" predict amyloid β pathology? A digitally supported multimodal lifestyle program to promote brain health among older adults (the LETHE randomized controlled feasibility trial): study design, progress, and first results. Unveiling the molecular mechanisms of Danggui-Shaoyao-San against Alzheimer's disease in APP/PS1 mice via integrating proteomic and metabolomic approaches. Age of onset moderates the effects of Vascular Risk Factors on Neurodegeneration, Blood-Brain-Barrier permeability, and cognitive decline in Alzheimer's Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1